NM
VNDA icon

Newtyn Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Newtyn Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-311,000
Closed -$1.28M – 46
2024
Q1 		$1.28M Buy
311,000
+21,000
+7% +$84.1K 0.25% 35
2023
Q4 		$1.22M Buy
+290,000
New +$1.17M 0.24% 36

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Newtyn Management's VNDA Position: Q2 2024 in Review

Newtyn Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2024, closing a stake of 311,000 shares — an estimated $1.28M sold.

Newtyn Management first reported a position in VNDA in Q4 2023 and held it in 2 quarters. The position peaked at $1.28M in Q1 2024. 148 funds tracked by Wall St. Rank hold VNDA as of Q2 2024.

  • Newtyn Management reported no remaining Vanda Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Newtyn Management sold 311,000 Vanda Pharmaceuticals shares in Q2 2024, an estimated $1.28M.
  • Newtyn Management first reported a position in Vanda Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Newtyn Management's Vanda Pharmaceuticals position peaked at $1.28M in Q1 2024.
  • 148 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2024.

Based on Newtyn Management's 13F filing for Q2 2024, filed 14 Aug 2024.